Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised …
Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …
Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
Inflammatory bowel disease (IBD) is an idiopathic chronic inflammatory disease of the
gastrointestinal system. The spectrum is of predominantly two types, namely, ulcerative …
gastrointestinal system. The spectrum is of predominantly two types, namely, ulcerative …
Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease
Inflammatory bowel diseases (IBD), namely Crohn's disease and ulcerative colitis, are
burdened by high medical costs which are mostly dependent on hospital inpatient treatment …
burdened by high medical costs which are mostly dependent on hospital inpatient treatment …
knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization
Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been
approved by the European Medical Agency for all immune-mediated inflammatory diseases …
approved by the European Medical Agency for all immune-mediated inflammatory diseases …
Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme
V Razanskaite, M Bettey, L Downey… - Journal of Crohn's …, 2017 - academic.oup.com
Abstract Background and Aims: Biosimilar infliximab CT-P13 offers the potential for large
drug acquisition cost savings. However, there are limited published data regarding its …
drug acquisition cost savings. However, there are limited published data regarding its …
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
S Fischer, S Cohnen, E Klenske… - Therapeutic …, 2021 - journals.sagepub.com
Background: Long-term data on inflammatory bowel disease (IBD) patients switched from
originator to biosimilar infliximab SB2 are lacking. The aim of the conducted study was to …
originator to biosimilar infliximab SB2 are lacking. The aim of the conducted study was to …
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience
R Ratnakumaran, N To, DJ Gracie… - Scandinavian journal …, 2018 - Taylor & Francis
Objectives: Recently, the infliximab biosimilar (CT-P13) received market authorisation for
inflammatory bowel disease (IBD), allowing cost benefits when switching to CT-P13. We aim …
inflammatory bowel disease (IBD), allowing cost benefits when switching to CT-P13. We aim …
Belgian IBD Research Group [BIRD] position statement 2019 on the use of adalimumab biosimilars in inflammatory bowel diseases
M Somers, P Bossuyt, M Ferrante… - Journal of Crohn's …, 2020 - academic.oup.com
The emergence of biosimilars is generally considered as an opportunity to guarantee
accessibility to affordable treatments and to enhance financial sustainability of national …
accessibility to affordable treatments and to enhance financial sustainability of national …
Practical management of biosimilar use in inflammatory bowel disease (ibd): a global survey and an international delphi consensus
As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective
alternatives within healthcare systems. Addressing various challenges in the clinical …
alternatives within healthcare systems. Addressing various challenges in the clinical …
An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease
Objective We aimed to evaluate the efficacy and safety of infliximab biosimilar, CT-P13, for
patients with inflammatory bowel disease. Methods We searched PubMed, Scopus, Ovid …
patients with inflammatory bowel disease. Methods We searched PubMed, Scopus, Ovid …